公开(公告)号：US08598361B2

公开(公告)日：2013-12-03

申请号：US13347926

申请日：2012-01-11

Applicant: Juan-Miguel Jimenez ,  Andrew Miller ,  Philip Collier ,  Jeremy Green ,  Albert Dros ,  Huai Gao ,  Sylvain Hamon

Inventor： Juan-Miguel Jimenez ,  Andrew Miller ,  Philip Collier ,  Jeremy Green ,  Albert Dros ,  Huai Gao ,  Sylvain Hamon

IPC: C07D215/04

CPC classification number: C07D471/04

Abstract: The present invention relates to a process for the synthesis of 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine in high yield and purity. The present invention also relates to processes for the synthesis of 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine derivatives. These processes are useful for preparing biologically active compounds, particularly certain GSK-3 inhibitors, or derivatives thereof.

Abstract translation: 本发明涉及以高产率和纯度合成5-氟-1H-吡唑并[3,4-b]吡啶-3-胺的方法。 本发明还涉及5-氟-1H-吡唑并[3,4-b]吡啶-3-胺衍生物的合成方法。 这些方法可用于制备生物活性化合物，特别是某些GSK-3抑制剂或其衍生物。

公开(公告)号：US20130096302A1

公开(公告)日：2013-04-18

申请号：US13650586

申请日：2012-10-12

Applicant: Hayley Binch ,  Daniel Robinson ,  Damien Fraysse ,  Andrew Miller

Inventor： Hayley Binch ,  Daniel Robinson ,  Damien Fraysse ,  Andrew Miller

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to compounds useful as inhibitors of Aurora protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

Abstract translation: 本发明涉及可用作Aurora蛋白激酶抑制剂的化合物。 本发明还提供包含所述化合物的药学上可接受的组合物和使用该组合物治疗各种疾病，病症或病症的方法。 本发明还提供了制备本发明化合物的方法。

公开(公告)号：US08422408B2

公开(公告)日：2013-04-16

申请号：US11848894

申请日：2007-08-31

Applicant: Mark W. Stober ,  Kiran Patel ,  Jyothival Shivan ,  Andrew Miller ,  Sutap Chatterjee ,  Khalid Ahmed

Inventor： Mark W. Stober ,  Kiran Patel ,  Jyothival Shivan ,  Andrew Miller ,  Sutap Chatterjee ,  Khalid Ahmed

IPC: H04L12/16

CPC classification number: H04L63/08 ,  H04L65/103 ,  H04L65/1069 ,  H04M3/4234 ,  H04M7/1205

Abstract: A device receives a request from an Internet Protocol (IP)-based device to create a virtual extension of a plain old telephone service (POTS)-based telephone line, authenticates the IP-based device for association with the POTS-based telephone line, and creates the virtual extension of the POTS-based telephone line to the IP-based device when the IP-based device is authenticated.

Abstract translation: 设备接收来自基于互联网协议（IP）的设备的请求以创建基于普通旧电话服务（POTS）的电话线的虚拟扩展，认证基于IP的设备以与基于POTS的电话线路相关联， 并且当基于IP的设备被认证时，创建基于POTS的电话线的虚拟扩展到基于IP的设备。

公开(公告)号：US08372835B2

公开(公告)日：2013-02-12

申请号：US12847136

申请日：2010-07-30

Applicant: Hayley Binch ,  Daniel Robinson ,  Damien Fraysse ,  Andrew Miller

Inventor： Hayley Binch ,  Daniel Robinson ,  Damien Fraysse ,  Andrew Miller

IPC: A01N43/58 ,  A01N43/60 ,  A61K31/50 ,  A61K31/495

CPC classification number: C07D487/04 ,  C07D471/04

Abstract: The present invention relates to compounds useful as inhibitors of Aurora protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

Abstract translation: 本发明涉及可用作Aurora蛋白激酶抑制剂的化合物。 本发明还提供包含所述化合物的药学上可接受的组合物和使用该组合物治疗各种疾病，病症或病症的方法。 本发明还提供了制备本发明化合物的方法。

公开(公告)号：US08268829B2

公开(公告)日：2012-09-18

申请号：US12436407

申请日：2009-05-06

Applicant: Jean-Damien Charrier ,  Francesca Mazzei ,  David Kay ,  Andrew Miller

Inventor： Jean-Damien Charrier ,  Francesca Mazzei ,  David Kay ,  Andrew Miller

IPC: C07D403/14 ,  A61K31/4155

CPC classification number: C07D403/14 ,  C07D239/34 ,  C07D401/14 ,  C07D403/12 ,  C07D453/02

Abstract: The present invention provides a facile process for the preparation of tri- and tetra-substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora-mediated diseases or conditions.

Abstract translation: 本发明提供了制备三取代和四取代嘧啶的简便方法。 该方法可用于制备蛋白激酶抑制剂，特别是Aurora激酶。 这些抑制剂可用于治疗或减轻Aurora介导的疾病或病症的严重性。

公开(公告)号：US20120232275A1

公开(公告)日：2012-09-13

申请号：US13347926

申请日：2012-01-11

Applicant: Juan-Miguel Jimenez ,  Philip Collier ,  Jeremy Green ,  Andrew Miller ,  Huai Gao ,  Sylvain Loic Jean-Luc Hamon ,  Albert Cornelis Dros

Inventor： Juan-Miguel Jimenez ,  Philip Collier ,  Jeremy Green ,  Andrew Miller ,  Huai Gao ,  Sylvain Loic Jean-Luc Hamon ,  Albert Cornelis Dros

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: The present invention relates to a process for the synthesis of 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine in high yield and purity. The present invention also relates to processes for the synthesis of 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine derivatives. These processes are useful for preparing biologically active compounds, particularly certain GSK-3 inhibitors, or derivatives thereof.

Abstract translation: 本发明涉及以高产率和纯度合成5-氟-1H-吡唑并[3,4-b]吡啶-3-胺的方法。 本发明还涉及5-氟-1H-吡唑并[3,4-b]吡啶-3-胺衍生物的合成方法。 这些方法可用于制备生物活性化合物，特别是某些GSK-3抑制剂或其衍生物。

公开(公告)号：US08239022B2

公开(公告)日：2012-08-07

申请号：US12356420

申请日：2009-01-20

Applicant: Andrew Miller

Inventor： Andrew Miller

IPC: A61N1/368

CPC classification number: A61B5/04525 ,  A61B5/0464

Abstract: A ventricular rate based on first candidate waveforms and second candidate waveforms within sensed ventricular waveforms is compared to an atrial rate. If the ventricular rate exceeds the atrial rate, the first candidate waveforms and second candidate waveforms are compared to a ventricular polarization complex template to obtain a first morphology indicator and a second morphology indicator. If a morphology match inconsistency is present, the amount by which the ventricular rate exceeds the atrial rate is compared to a threshold. If the threshold is exceeded, high-ventricular-rate therapy to the heart is inhibited. The ventricular polarization complex template may be a QRS-complex template, in which case a match inconsistency is present if each of the first candidate waveforms and the second candidate waveforms do not match the QRS-complex template. Alternatively, the ventricular polarization complex template may be a T-wave template, in which case a match inconsistency is present if either of the first candidate waveforms and the second candidate waveforms matches the T-wave template.

Abstract translation: 将基于感测的心室波形内的第一候选波形和第二候选波形的心室率与心房率进行比较。 如果心室率超过心房率，则将第一候选波形和第二候选波形与心室极化复合模板进行比较，以获得第一形态学指标和第二形态学指标。 如果存在形态匹配不一致，则将心室率超过心房率的量与阈值进行比较。 如果超过阈值，则抑制对心脏的高心率率治疗。 心室极化复合物模板可以是QRS复合模板，在这种情况下，如果第一候选波形和第二候选波形中的每一个与QRS复杂模板不匹配，则存在匹配不一致。 或者，心室极化复合模板可以是T波模板，在这种情况下，如果第一候选波形和第二候选波形中的任一个与T波模板匹配，则存在匹配不一致。

公开(公告)号：US20100185111A1

公开(公告)日：2010-07-22

申请号：US12356420

申请日：2009-01-20

Applicant: Andrew Miller

Inventor： Andrew Miller

IPC: A61B5/0402

CPC classification number: A61B5/04525 ,  A61B5/0464

Abstract: A ventricular rate based on first candidate waveforms and second candidate waveforms within sensed ventricular waveforms is compared to an atrial rate. If the ventricular rate exceeds the atrial rate, the first candidate waveforms and second candidate waveforms are compared to a ventricular polarization complex template to obtain a first morphology indicator and a second morphology indicator. If a morphology match inconsistency is present, the amount by which the ventricular rate exceeds the atrial rate is compared to a threshold. If the threshold is exceeded, high-ventricular-rate therapy to the heart is inhibited. The ventricular polarization complex template may be a QRS-complex template, in which case a match inconsistency is present if each of the first candidate waveforms and the second candidate waveforms do not match the QRS-complex template. Alternatively, the ventricular polarization complex template may be a T-wave template, in which case a match inconsistency is present if either of the first candidate waveforms and the second candidate waveforms matches the T-wave template.

Abstract translation: 将基于感测的心室波形内的第一候选波形和第二候选波形的心室率与心房率进行比较。 如果心室率超过心房率，则将第一候选波形和第二候选波形与心室极化复合模板进行比较，以获得第一形态学指标和第二形态学指标。 如果存在形态匹配不一致，则将心室率超过心房率的量与阈值进行比较。 如果超过阈值，则抑制对心脏的高心率率治疗。 心室极化复合物模板可以是QRS复合模板，在这种情况下，如果第一候选波形和第二候选波形中的每一个与QRS复杂模板不匹配，则存在匹配不一致。 或者，心室极化复合模板可以是T波模板，在这种情况下，如果第一候选波形和第二候选波形中的任一个与T波模板匹配，则存在匹配不一致。

公开(公告)号：US20090314244A1

公开(公告)日：2009-12-24

申请号：US12488853

申请日：2009-06-22

Applicant: Qingmin Yang ,  Andrew Miller ,  Frank Zlamal

Inventor： Qingmin Yang ,  Andrew Miller ,  Frank Zlamal

IPC: F02F3/00 ,  F02B75/32

CPC classification number: F16J1/16 ,  F16C7/023 ,  F16C9/04 ,  F16J1/08 ,  Y10T29/49249 ,  Y10T29/49266 ,  Y10T29/49288 ,  Y10T74/2142 ,  Y10T74/2162 ,  Y10T74/2173

Abstract: A piston assembly and method of assembly thereof, a wrist pin, a piston, a connecting rod, and methods of construction thereof is provided. The assembly includes a piston body having a pair laterally spaced pin bosses with a feature to prevent relative rotation of a first wrist pin member. The assembly has a connecting rod with a small end bore extending along a central axis and allowing relative rotation of the first wrist pin member and a feature with the small end bore to prevent relative rotation of a second wrist pin member. The first and second wrist pin members are moveable relative to one another, wherein the first and second members extend substantially parallel to the central axis through the small end bore.

Abstract translation: 提供一种活塞组件及其组装方法，一种腕针，活塞，连杆及其结构的方法。 组件包括具有一对侧向间隔开的销凸起的活塞体，具有防止第一腕销构件相对旋转的特征。 组件具有连接杆，其具有沿着中心轴线延伸的小端孔，并且允许第一腕针构件和具有小端孔的特征相对旋转以防止第二腕针构件相对旋转。 第一和第二腕销构件可相对于彼此移动，其中第一和第二构件基本平行于中心轴线延伸穿过小端孔。

公开(公告)号：US20080075763A1

公开(公告)日：2008-03-27

申请号：US11868184

申请日：2007-10-05

Applicant: Andrew Miller ,  Robert Cooper ,  Christopher Etheridge

Inventor： Andrew Miller ,  Robert Cooper ,  Christopher Etheridge

IPC: A61K9/127 ,  A61K31/56 ,  A61K31/711 ,  C07J9/00 ,  A61P43/00 ,  A61K48/00

CPC classification number: A61K9/1272 ,  A01K2207/05 ,  A01K2227/105 ,  A01K2267/0393 ,  A61K31/56 ,  A61K31/711 ,  C07J9/00 ,  C07J41/0055

Abstract: A method for treating genetic disorders or conditions or diseases in patients in need of such treatments. The method includes administering an effective amount of a compound comprising a cholesterol group or derivative thereof having linked thereto a head group. The head group is more positive than the heat group of DC-Chol. The heat group may be a straight chain polymeric group having two or more amine groups separated by an ethylene group.

Abstract translation: 用于治疗需要这种治疗的患者的遗传疾病或病症或疾病的方法。 该方法包括施用有效量的包含与头基连接的胆固醇基或其衍生物的化合物。 头组比DC-Chol的热组更积极。 该热基团可以是具有两个或更多个被乙烯基团隔开的胺基的直链聚合基团。